Evolus, Inc.

Evolus, Inc. is currently considered risky and overvalued due to troubling financial metrics, including a Price to Book Value of -98.02 and a P/E ratio of -8.2365, alongside a significant stock return decline of -60.42% over the past year compared to the S&P 500's 17.14% return.

Evolus, Inc. is currently considered risky and overvalued, with troubling financial metrics such as a Price to Book Value of -98.02, an EV to EBITDA ratio of -23.65, and a P/E ratio of -12.3086, all indicating significant underperformance compared to its peers and the S&P 500.

As of April 3, 2025, Evolus, Inc. is in a bearish trend with moderate strength, indicated by bearish MACD and moving averages, along with mildly bearish Bollinger Bands, and no immediate reversal signals from RSI or Dow Theory.

As of March 2022, the management team of Evolus, Inc. includes Chairman Vikram Malik, CEO David Moatazedi, and several directors: Simone Blank, Peter Farrell, David Gill, Robert Hayman, and Karah Parschauer. They oversee the company's strategic direction and governance.

Evolus, Inc. is a medical aesthetics company specializing in aesthetic procedures and treatments, with recent net sales of $69 million and a net loss of $19 million. It has a market cap of $596.40 million and operates in the Pharmaceuticals & Biotechnology industry.

As of Jun 18, Evolus, Inc. has a market capitalization of 596.40 million and reported net sales of 275.47 million with a net profit of -56.20 million over the latest four quarters.